Mylan Australia Pty Limited Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Mylan Australia Pty Limited Pharmaceutical Import Records from India — 3 Products, $4.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mylan Australia Pty Limited — Pharmaceutical Importer Profile (2026) | 3 Products, $4.8M Trade | TransData Nexus

Mylan Australia Pty Limited

Pharmaceutical Importer · Australia · Advanced Antibiotics Focus · $4.8M Total Trade · DGFT Verified

Mylan Australia Pty Limited is a pharmaceutical importer based in Australia with a total trade value of $4.8M across 3 products in 3 therapeutic categories. Based on 133 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Mylan Australia Pty Limited sources from 2 verified Indian suppliers, with Medreich Limited accounting for 99.4% of imports.

Mylan Australia Pty Limited — Import Portfolio & Supplier Network

Mylan Australia Pty Limited import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mylan Australia Pty Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medreich Limited	$7.5M	262	99.4%
12/8 Saraswathi Ammal Street	$41.6K	2	0.6%

Mylan Australia Pty Limited sources from 2 verified Indian suppliers across 149 distinct formulations. The sourcing is — Medreich Limited accounts for 99.4% of total imports, indicating a strategic single-source relationship.

What Formulations Does Mylan Australia Pty Limited Import?

Formulation	Value	Ships
Amoxicillin capsules BP 500MG	$830.3K	18
Flucloxacillin capsules 500MG	$300.0K	6
Flucloxacillin capsules 500MG	$250.0K	5
Amoxicillin 875MG & clavulanic acid	$250.0K	5
Erythromycin ethylsuccinate powder for	$243.3K	17
Flucloxacillin capsules 500MG (staphylex500) 3x8s (115978 packs)	$150.0K	3
Flucloxacillin capsules 500MG (staphylex500) 3x8s (116038 packs)	$150.0K	3
Amoxicillin capsules BP 500MG (alphamox500) 2x10s (133560 packs)	$143.0K	3
Flucloxacillin capsules 500MG (staphylex500) 3x8s (77420 packs	$136.1K	3
Flucloxacillin capsules 500MG (staphylex500) 3x8s (77360 packs	$133.1K	3
E-mycin (erythromycin ethylsuccinate TAB	$105.7K	3
Dicloxacillin 500MG capsules (dicloxacillin mylan 500MG) 24s (49624 packs	$100.4K	3
Flucloxacillin capsules 500 MG	$100.0K	2
Flucloxacillin capsules 500MG staphylex500 3x8s 116010	$100.0K	2
Amoxicillin 875MG and clavulanic acid 125MG tablets(alphaclav duo forte 875/125tablets)1x10s (100000 packs)	$100.0K	2

Mylan Australia Pty Limited imports 149 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Flucloxacillin	Advanced Antibiotics	$3.6M	73	9.4%	2
2	Erythromycin	Antibiotics	$1.1M	54	1.3%	6
3	Brufen	Brand Names & OTC Products	$47.1K	6	1.0%	14

Mylan Australia Pty Limited imports 3 pharmaceutical products across 3 categories into Australia totaling $4.8M.

Mylan Australia Pty Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mylan Australia Pty Limited is an Australian proprietary company specializing in the importation and distribution of finished pharmaceutical formulations. Established on August 10, 2007, the company is headquartered in New South Wales, Australia. It operates under the Australian Company Number (ACN) 126 990 029 and the Australian Business Number (ABN) 15 126 990 029.

As a subsidiary of Viatris Inc., Mylan Australia plays a pivotal role in the Australian pharmaceutical supply chain by sourcing and importing a diverse range of pharmaceutical products. The company's portfolio encompasses various therapeutic categories, including advanced antibiotics, general antibiotics, and brand-name over-the-counter (OTC) products. This strategic focus enables Mylan Australia to meet the evolving healthcare needs of the Australian market.

2Distribution Network

Mylan Australia Pty Limited's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across Australia. While specific warehouse locations and logistics capabilities are not publicly disclosed, the company's operations are centralized in New South Wales, with a registered address at Level 1, 30 Hickson Road, Millers Point, NSW 2000. This centralization facilitates streamlined distribution processes and effective coordination with suppliers and healthcare providers nationwide.

3Industry Role

In Australia's pharmaceutical supply chain, Mylan Australia Pty Limited functions primarily as a pharmaceutical importer and distributor. The company sources finished pharmaceutical formulations from international suppliers, particularly from India, and supplies these products to various stakeholders within the Australian healthcare system. By importing a range of pharmaceutical products, Mylan Australia contributes to the diversity and availability of medications in the Australian market, catering to both generic and brand-name segments.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mylan Australia Pty Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Mylan Australia Pty Limited demonstrates a high degree of sourcing concentration, with a significant portion of its pharmaceutical imports originating from a single supplier, MEDREICH LIMITED. Between 2022 and 2026, MEDREICH LIMITED accounted for approximately 99.4% of Mylan Australia's total import value from India, amounting to $7.5 million across 262 shipments. This substantial reliance indicates a strategic partnership, potentially offering benefits such as favorable pricing, consistent product quality, and reliable supply chain management.

However, this concentration also presents potential risks. Any disruptions affecting MEDREICH LIMITED—such as production issues, regulatory challenges, or geopolitical events—could impact Mylan Australia's ability to meet market demand. To mitigate such risks, it would be prudent for Mylan Australia to diversify its supplier base and establish contingency plans to ensure a resilient supply chain.

2Supply Chain Resilience

The resilience of Mylan Australia Pty Limited's supply chain is closely tied to its reliance on MEDREICH LIMITED as the primary supplier of pharmaceutical products. While this partnership offers advantages in terms of consistency and potential cost savings, it also exposes the company to risks associated with single-source dependency. To enhance supply chain resilience, Mylan Australia could consider engaging with additional suppliers to diversify its sourcing strategy. This approach would provide alternative options in the event of supply disruptions and contribute to a more robust and adaptable supply chain.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the Therapeutic Goods Administration (TGA) is the primary regulatory authority responsible for overseeing the safety, efficacy, and quality of therapeutic goods, including pharmaceuticals. The TGA operates under the Therapeutic Goods Administration Act 1989, which provides the legislative framework for regulating medicines and medical devices in Australia.

For Indian pharmaceutical products to be imported and marketed in Australia, they must undergo a rigorous evaluation process by the TGA. This process includes assessing the product's quality, safety, and efficacy, as well as ensuring compliance with Australian standards and regulations. The TGA's role is crucial in maintaining the integrity of the Australian pharmaceutical market and protecting public health.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Australia are stringent. Importers must hold a valid license issued by the TGA, which authorizes them to import therapeutic goods into the country. This license ensures that importers adhere to regulatory standards and maintain the quality and safety of the products they distribute.

Good Manufacturing Practice (GMP) certification is a critical component of the import process. The TGA recognizes GMP certifications from various international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Pharmaceutical products imported into Australia must be manufactured in facilities that hold valid GMP certifications from these recognized authorities. This requirement ensures that imported medicines meet the high-quality standards expected in the Australian market.

Mylan Australia Pty Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Mylan Australia Pty Limited's focus on importing advanced antibiotics, general antibiotics, and brand-name OTC products aligns with the therapeutic needs of the Australian population. The high import value of flucloxacillin, an advanced antibiotic, indicates a significant demand for this medication in the Australian market. Similarly, the inclusion of erythromycin and brufen in the product portfolio reflects the company's strategy to provide a comprehensive range of antibiotics and pain management solutions.

The decision to import brand-name OTC products suggests a strategic approach to cater to consumer preferences for established and trusted brands. By offering a mix of generic and brand-name products, Mylan Australia can address a broad spectrum of market needs, from cost-effective generic options to premium brand-name medications.

2Sourcing Profile

Mylan Australia Pty Limited's sourcing strategy is heavily centered on importing finished pharmaceutical formulations from India, particularly from MEDREICH LIMITED. This focus allows the company to leverage India's robust pharmaceutical manufacturing capabilities and cost advantages. The preference for finished formulations over active pharmaceutical ingredients (APIs) indicates a strategic decision to streamline operations and ensure product quality and consistency.

By sourcing from a single supplier, Mylan Australia can establish strong partnerships and negotiate favorable terms. However, this approach also necessitates careful risk management to mitigate potential supply chain disruptions. Diversifying the supplier base could enhance supply chain resilience and provide access to a broader range of products.

Seller's Guide — How to Become a Supplier to Mylan Australia Pty Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Mylan Australia Pty Limited's supply chain. While the company currently relies heavily on MEDREICH LIMITED, the diversification of its supplier base could lead to improved supply chain

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Mylan Australia Pty Limited

What products does Mylan Australia Pty Limited import from India?

Mylan Australia Pty Limited imports 3 pharmaceutical products across 3 categories. Top imports: Flucloxacillin ($3.6M), Erythromycin ($1.1M), Brufen ($47.1K).

Who supplies pharmaceuticals to Mylan Australia Pty Limited from India?

Mylan Australia Pty Limited sources from 2 verified Indian suppliers. The primary supplier is Medreich Limited (99.4% of imports, $7.5M).

What is Mylan Australia Pty Limited's total pharmaceutical import value?

Mylan Australia Pty Limited's total pharmaceutical import value from India is $4.8M, based on 133 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mylan Australia Pty Limited focus on?

Mylan Australia Pty Limited imports across 3 categories. The largest: Advanced Antibiotics (76.6%), Antibiotics (22.4%), Brand Names & OTC Products (1.0%).

Get Full Mylan Australia Pty Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.